Biofactories Applied to Future Antivenom Production

Posted by
  Image Credit: By Ssiltane - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=52242648 Biofactories Applied to Future Antivenom Production Abstract Background: Accidents caused by the  Loxosceles laeta  spider constitute a health problem in South America. Envenomation can lead to severe systemic manifestations, eventually compromising the patient’s life. Most regional health authorities consider antivenom administration the basis of effective treatment in the most serious cases. The availability of spider venom is the primary bottleneck for antivenom production. Herein, we present a novel biotechnological approach, based on the expression of recombinant versions of the most relevant toxin in loxoscelism, sphingomyelinase D (SphD), in insect larvae ( Spodoptera frugiperda ).  Methods: We produced two versions of SphD: one conserving its biological activities (wtSphD) and a second alternative that was designed to be genetically detoxified (dSphD...

Large animal models for the assessment of snakebite envenoming therapies

Posted by

 


Large animal models for the assessment of snakebite envenoming therapies


Abstract

Snakebite envenoming causes over 100,000 deaths annually, creating a need for more effective therapies. Traditionally, most preclinical testing relies on murine models with limited translational value. This review highlights the value of large animal models, particularly sheep and pigs, for studying venom toxicokinetics and antibody and small-molecule pharmacokinetics. Implementing clear guidelines and standardized endpoints in large-animal studies could help advance the clinical translation of new snakebite treatments.

Benard-Valle, M., Ahmadi, S., Modahl, C. M., Neri-Castro, E., Alagón, A., Boyer, L., Ljungars, A., & Laustsen, A. H. (2026). Large animal models for the assessment of snakebite envenoming therapies. Npj Drug Discovery, 3(1), 12. https://doi.org/10.1038/s44386-026-00043-8